The boom times live on for the health and beauty sector, according to the latest research by Verdict Research, which provides research and consultancy services covering UK and European retail markets.
Read
Although the performance of the AIM Index proved largely flat over the past month, there were, as ever, a number of extravagant movements among its individual constituents.
Read
Pharmaceuticals giant GlaxoSmithKline beat a retreat after US research indicated its second-best-selling drug, diabetes treatment Avandia, raised the risk of heart attacks.
Read
Global quoted biotechnology sales topped a staggering £35 billion
last year and the recent success within the sector is being reflected
in record merger and acquisition premiums, informs a new report
from Ernst & Young.
Read
The recent decision by the EU to fund embryonic stem cell research — and the USA’s opposing move — may act to strengthen the UK in this area, says the DTI.
Read
TeGenero, the German biotech firm at the centre of March’s disastrous West London drug trials, has filed for bankruptcy, with management citing an inability to secure additional funding as the reason for the move.
Read
The primary health care market has been the subject of much debate this month
Read
Pharmaceutical and healthcare industry consultant IMS Health has broken down global pharmaceutical sales for 2005 in an intriguing report.
Read
Novel methods of delivering drugs have received a boost this month, after pharmaceutical giant Pfizer received regulatory approval for Exubera in both the EU and US.
Read
Smith & Nephew, the UK’s largest maker of orthopaedic implants such as artificial hips, was forced to warn that sales would be hit in the current year, because of the closure of hospitals in the Gulf States of the US affected by Hurricane Katrina. Insurers aside, this was the first warning from a UK company citing the disaster as affecting trading.
Read
